What's Going On With Novavax Stock Thursday?
Portfolio Pulse from Adam Eckert
Novavax Inc (NASDAQ:NVAX) shares are trading higher after the FDA's advisory committee recommended updating COVID-19 vaccines to target the JN.1 variant. Novavax plans to deliver the updated vaccine by September and expects commercial sales under Emergency Use Authorization for the 2024-2025 season.
June 06, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax shares are up 13% following the FDA advisory committee's recommendation to update COVID-19 vaccines for the JN.1 variant. Novavax plans to deliver the updated vaccine by September and expects commercial sales under Emergency Use Authorization for the 2024-2025 season.
The FDA advisory committee's unanimous recommendation to update COVID-19 vaccines for the JN.1 variant is a significant positive development for Novavax. The company's plan to deliver the updated vaccine by September and the expectation of commercial sales under Emergency Use Authorization for the 2024-2025 season further boost investor confidence, leading to a 13% increase in share price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100